ArticleInternational journal of telemedicine and applications2026
CERV-Score: A Hybrid Machine Learning Framework for Cervical Cancer Risk Prediction Using Integrated Clinical and Genomic Data.
Article in International journal of telemedicine and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CERV-Score: A Hybrid Machine Learning Framework for Cervical Cancer Risk Prediction Using Integrated Clinical and Genomic Data.International journal of telemedicine and applications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer remains a major global health burden, particularly in underserved populations where late diagnoses contribute to high mortality rates. Accurate, early risk prediction is essential for improving outcomes and guiding preventive care. In this study, we introduce CERV-Score, a hybrid machine learning framework that advances prior approaches by combining structured clinical risk factors with recurrence-based genomic markers to generate continuous, probabilistic risk scores rather than traditional binary classifications. This enables nuanced patient stratification into low, moderate, and high-risk categories, providing clinicians with more actionable insights. Unlike previous models, CERV-Score integrates genomic recurrence analysis identifying genes consistently expressed across multiple RNA-seq samples to improve biological relevance and robustness. Additionally, we developed an interactive clinical-genomic decision support tool that delivers real-time, percentage-based risk predictions and includes a gene lookup function, bridging clinical practice and molecular exploration in a single platform. The hybrid CERV-Score model achieved high predictive performance (accuracy = 94.1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.